ArticleJournal of cancer research and clinical oncology2025
Global, regional, and national burden of ovarian cancer in women aged 45 + from 1990 to 2021 and projections for 2050: a systematic analysis based on the 2021 global burden of disease study.
Article in Journal of cancer research and clinical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed.
- Evaluation of Phytocannabinoids as Antitumor Agents against Ovarian Cancer Cells in Combination with Carboplatin.ACS omega · 2026Article
- Current Evidence Linking Microplastic Exposure and Reproductive Cancers.Journal of xenobiotics · 2026Review
- Is Follicle-Stimulating Hormone (FSH) Misnamed? Rethinking Its Role in Menopause as a Systemic Regulator of Bone, Brain, Metabolism, and Aging.Journal of clinical medicine · 2026Review
- Preoperative Inflammatory Markers as Predictors of Ovarian Tumor Malignancy: A Retrospective Diagnostic Study.Medicina (Kaunas, Lithuania) · 2026Observational
- Fagotti Score (FS) Compared with Peritoneal Cancer Index (PCI) for Preoperative Assessment of Optimal Cytoreduction in Upfront Laparoscopy.Current oncology (Toronto, Ont.) · 2026Article
- Neutrophil extracellular traps (NETosis) in gynecologic cancers: from pathogenesis to therapeutic opportunities: a narrative review.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Review
- Emerging molecular targets in gynaecologic cancers: clinical implications for personalized therapy.Molecular biology reports · 2026Review
- The role of circadian disruption, sleep dysregulation, lifestyle factors, and metabolic reprogramming in the pathogenesis and progression of ovarian cancer.Journal of the National Cancer Center · 2026Review
- Analysis of ovarian cancer burden among reproductive-aged women and its association with the socio-demographic index from 1990 to 2021.World journal of surgical oncology · 2026Article
- Ovarian cancer.Nature reviews. Disease primers · 2026Review
- Article
- Article
- Burden and Trends of Six Gynecological Diseases Among Chinese Women Aged 15-49 Years, 1990-2021: Evidence from GBD 2021.International journal of women's health · 2026Article
- A cross-validated deep learning framework for automated detection of DMBA-induced ovarian cancer from histopathological images with CA-125 biomarker support.Frontiers in artificial intelligence · 2026Article
- Case Report: Durable response to mirvetuximab soravtansine in a patient with platinum-sensitive ovarian cancer and a diagnosis of myelodysplastic syndrome.Frontiers in oncology · 2026Article
- Higher dietary phytochemical index is associated with lower risk of epithelial ovarian cancer in Chinese women: a case-control study.Frontiers in nutrition · 2026Article
- Treatment sequence of stem cell delivered heterologous oncolytic virus impact on tumor microenvironment in immunocompetent ovarian cancer model.Frontiers in immunology · 2026Article
- Global, regional, and national burden of smoking-attributable digestive cancers in adults aged ≥60 years, 1990-2021, with projections to 2036: A secondary dataset analysis of Global Burden of Disease (GBD) 2021.Tobacco induced diseases · 2026Article
- Global, regional, and national burden of ovarian cancer and uterine cancer attributable to high BMI, 1990-2021: analysis of data from the global burden of disease study 2021.Frontiers in oncology · 2026Article
- Global burden of ovarian cancer attributable to high BMI, 1990-2021: spatiotemporal trends, risk factors, frontier analysis, and projections to 2036 based on GBD 2021 study.Journal of ovarian research · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
purposeOvarian cancer is the most common cause of gynecologic cancer-related deaths. We aimed to assess the global, regional, and national burdens and trends of Ovarian Cancer in Women Aged 45 + from 1990 to 2019 and Projections for 2050, utilizing data from the most recent Global Burden of Disease (GBD) 2021 database.
methodsAge-standardized rates of incidence, prevalence, mortality, and disability-adjusted life years (DALYs) were analyzed using GBD 2021 data. Temporal trends were assessed using estimated annual percentage change (EAPC). Regional disparities were examined via the Socio-Demographic Index (SDI). Age-Period-Cohort (APC) models assessed disease dynamics, while Bayesian APC (BAPC) modeling projected trends to 2050.
resultsIn 2021, global ovarian cancer incidence, prevalence, mortality, and DALYs in women aged 45 + were 239,682; 843,405; 171,246; and 4,352,539, respectively. The global burden declined significantly from 1990 to 2021 and is projected to remain stable through 2050. However, regional disparities persist: High and High-middle SDI regions saw decreases, while Middle to Low SDI regions experienced increases. Burden increased with SDI up to 0.8, then declined. Population growth was the primary contributor, followed by epidemiologic transitions and aging. The 55-59 age group showed the highest morbidity and DALYs; mortality peaked at 65-69 years.
conclusionsAlthough the overall burden of ovarian cancer in women aged 45 + is declining globally, marked regional disparities underscore the need for tailored prevention and treatment strategies to further reduce disease impact and improve outcomes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.